A large clinical trial, despite showing no significant clinical improvement in patients with stable COPD following a regimen of four monthly intravenous MSC infusions, demonstrated a reduction in circulating C‐reactive protein (CRP) after 1 month, suggesting that intravenous MSC infusion may alter systemic inflammation in patients with COPD.8 Here, CRP is linked to chronic obstructive pulmonary disease.